This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
This piece evaluates performance in retirement for Sp 500 vs Multi Asset approaches, outlining where each may excel under different conditions.
26,383 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Deribit and SignalPlus unveil The Island, a 35-day crypto trading contest with a prize pool of up to $600,000 USDC. T...
Meta’s legal exposure has surged to roughly $1.4 trillion ahead of a high-stakes August 2026 trial, testing how inves...
Analysts point to a stronger data center drive and autos growth as Qualcomm edges toward a new rally. With a $258 tar...
Jeff Bezos-led Blue Origin plans a $10 billion external round at a $130 billion valuation, a move that reframes priva...
When a top executive sells a large block of stock, investors want to know whether it signals trouble or simply person...
More than 60 analysts now rate the stock Buy as investors await the upcoming earnings release and assess cloud, adver...
An executive chair's sizable stock sale draws attention. This piece explains what the numbers mean, how to read insid...
A mid-cap tech stock has quietly outperformed NVIDIA on a three-year price-return basis, triggering renewed interest ...
When a prominent hedge fund reports selling a large block of shares, it sparks questions about the stock’s future. Th...
A fresh, AI-driven marketing venture is selling Reg A+ shares at $0.85 to private investors, promising rapid ROI and ...
Cardano's price path through 2025 to 2030 hinges on network upgrades and DeFi growth. This analysis outlines base, bu...